Award NoticePosted Oct 1, 2025

Development Of a Concentrated Tranexamic Acid (TXA) Intramuscular Injection

Health and Human Services (all) · BARDA - ASPR / DAAPPO / BARDA DCMA

Stage
Awarded
NAICS
541714
Value
$186.0M
Solicitation
75A50125C00018
Set-aside
None stated
PSC
AN13
Place
Jerusalem, IL-JM, ISR
Contact
Erin Greninger, Contracting Officer (erin.greninger@hhs.gov)

No listed company matched (Materiality N/A)

Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 75A50125C00018 in this department, oldest first.

Early notice
None posted
Solicitation
None posted
Award
  • Oct 1, 2025 · this notice
    Award Notice
    RAFA LABORATORIES LTD · $186.0M

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Note the winner and the end of the period of performance for the recompete.
  • Follow the agency to see the next notice for this work.

What the notice says

This award is for the development of a concentrated Tranexamic Acid (TXA) Intramuscular Injection. The Government seeks this development in order to receive FDA approval for the concentrated IM TXA formulation that can be delivered in a pref-filled syringe or a dedicated autoinjector. This contract action was awarded competitively as a Cost Share Contract. A Cost Share Contract was used in accordance with FAR 35.006 (c) due to an absence of precise specifications and difficulties in estimating costs with accuracy.

Who won similar work

4 award notices on SAM.gov in the last 24 months. Matched by: Same office (BARDA - ASPR / DAAPPO / BARDA DCMA), same product/service code (PSC) AN13 and NAICS 541714.

Single-winner award sizes (4): middle half $75.8M to $159.6M, median $99.2M; range $7.5M to $339.2M.

WinnerAwardsValueLast
CIDARA THERAPEUTICS INC1$339.2MOct 14, 2025
Flosonics Medical LLC1$99.7MJun 5, 2026
OSIVAX Paris 8 �le-de-France 75008 FRA1$98.6MOct 14, 2025
ISOLA THERAPEUTICS INC1$7.5MApr 27, 2026

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

Latest awards

Competitive landscape

For the 4 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 0 of these past winners lobbied Health & Human Services, Dept of (HHS) since 2024 (0 filings)
  • 0 of their lobbyists list a past Health & Human Services, Dept of (HHS) job
  • No corporate PAC money from them to the overseeing committees since 2024
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 0 bills named on the past winners' lobbying filings
  • 253 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 0 of the past winners are listed companies
  • 0 insider buys and 0 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.